ANCA血管炎(Anca Vasculitis)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anca Vasculitis Overview 6
Therapeutics Development 7
Pipeline Products for Anca Vasculitis – Overview 7
Pipeline Products for Anca Vasculitis – Comparative Analysis 8
Anca Vasculitis – Therapeutics under Development by Companies 9
Anca Vasculitis – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Anca Vasculitis – Products under Development by Companies 13
Anca Vasculitis – Companies Involved in Therapeutics Development 14
Anthera Pharmaceuticals‚ Inc. 14
ChemoCentryx, Inc. 15
GlaxoSmithKline plc 16
Kineta, Inc. 17
Anca Vasculitis – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
belimumab – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
blisibimod – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CCX-1378 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CCX-1641 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CCX-168 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
dalazatide – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
mepolizumab – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Anca Vasculitis – Recent Pipeline Updates 42
Anca Vasculitis – Product Development Milestones 53
Featured News & Press Releases 53
Nov 17, 2014: ChemoCentryx’s Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 53
Jun 02, 2014: ChemoCentryx’s Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements 54
Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis 55
Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59